top of page

Search Results

Results found for "pain research"

  • Dr. GPCR Spotlights Revvity’s pHSense™ Internalization Tools

    Eric Trinquet, Director of Research and Development at Revvity.   A GPCR Internalization Tool Designed for Real Research Needs Built on more than two decade A GPCR Internalization Tool Designed for Real Research Needs s of GPCR assay innovation , pHSense™  was developed to overcome GPCR  is a global nonprofit platform advancing GPCR research  through education, community, and platform Its GPCR research tools  support discovery teams and academic labs with precision reagents and validated

  • Illuminating GPCR Research: FRET and BRET-Based Sensors Shed Light on Cellular Signaling

    Despite their immense potential, utilizing FRET and BRET sensors in GPCR research comes with challenges In conclusion, FRET and BRET-based sensors have transformed the landscape of GPCR research, offering

  • Differential binding of Δ9-tetrahydrocannabinol derivatives to type 1 cannabinoid receptors (CB1)

    Introduction Cannabinoid receptors are GPCRs, and two main types exist, CB1R and CB2R. occurring Δ9-tetrahydrocannabinolderivatives to cannabinoid CB1 and CB2 receptors, Pharmacological Research

  • Fluorescence based HTS compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells

    Thus, developing assays for commercially available probes such as CELT-419 would facilitate research For example, a Cy5-labelled fluorescent ligand with the same pharmacophore is available from Celtarys Research development of measurement methods can increase the quality and quantity of both fundamental receptor research An Order of Magnitude Faster DNA-PAINT Imaging by Optimized Sequence Design and Buffer Conditions.

  • Conjugation Strategies for Probe Development

    This is Lucía from the Celtarys Research chemistry team.  For our very first post in this ecosystem, we wanted to highlight a huge part of our work at Celtarys Research

  • Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for...

    August 2022 Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for US $900,000) of additional research funding. rights to develop certain retained compounds for Charcot-Marie-Tooth type 1A neuropathy (CMT1A) and pain

  • Anatomy of a partnership: Cancer Research UK teams up with Sosei Heptares

    August 2022 "August 10, 2022 Cancer Research UK is working with global biopharma Sosei Heptares on a Cancer Research UK, a charity dedicated to funding lifesaving oncology research, spent £388 million on cancer research last fiscal year. Much of that funding is distributed to support third party research, but the group also does its own research into promising therapy areas, working with partners who have a good idea but don’t have all

  • Dr. GPCR Updates

    Celtarys Research Joins Dr. GPCR – Precision Tools for GPCR Assays Dr. GPCR and Celtarys Research have teamed up. Full Breakdown of the Latest in GPCR Research Want detailed insights? Dive into this week’s research, tools, and biotech updates all in one place.

  • SYnAbs is now officially accredited as a Research Tax Credit by the French Ministry of Higher...

    August 2022 "We are proud to announce that SYnAbs is now officially accredited as a Research Tax Credit by the French Ministry of Higher Education and Research for 2022-2023-2024. antibodies #medicine #cancer #innovation #gpcr #synabs #monoclonalantibodies #drugdiscovery #biotechnology #research

  • Meet Peter McNamara, Ph.D., Tectonic’s SVP, Head of Research

    December 2021 "Meet Peter McNamara, Ph.D., Tectonic’s SVP, Head of Research.

  • Crinetics Presents Clinical And Research Results At ENDO 2022

    June 2022 "CRN04894 Selected for Oral Presentation SAN DIEGO, June 8, 2022 — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), announced that results from the company’s Phase 1 study of CRN04894, the company’s investigational candidate for the treatment of Cushing’s disease, congenital adrenal hyperplasia (CAH) and other conditions driven by excess adrenocorticotropic hormone (ACTH), were selected for an oral presentation at ENDO 2022, the Endocrine Society’s annual meeting. Crinetics recently reported that administration of CRN04894 reduced both serum cortisol levels and 24-hour urine free cortisol excretion in the presence of sustained, disease-like ACTH concentrations in multiple-ascending dose cohorts of a Phase 1 study." Read more at the source #DrGPCR #GPCR #IndustryNews

  • Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate ...

    July 2022 Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate company and world-leader in GPCR1-focused structure-based drug design (SBDD) and development, and Cancer Research UK, the world’s largest private funder of cancer research, today announce the signing of an agreement

  • Allosteric Binding Demystified: Smarter GPCR Drug Discovery

    In the realm of molecular research, precise interpretation is crucial; a misread curve can lead to lost Gain competitive clarity:  Learn how binding and function diverge, and why that divergence is the key Each week, you gain curated intelligence across science, careers, and strategy: Deep-dive expert lectures

  • New Tools, Smart Signals, and The Kenakin Brief

    Hello GPCR Trailblazers, This week, we’re spotlighting Celtarys Research, our newest partner, featured GPCR will help researchers move faster with custom fluorescent ligands, translational insight, and tool-enabled Introducing Celtarys - Probe Development via Conjugation Strategies   Celtarys Research's first article Explore this week’s research, tools, and biotech insights in one place. The insights are ready.

  • Understanding the Journey: Catherine Demery's Path to Addiction Science

    Learning the Lab, Learning Herself During her time at the contract research organization (CRO) in Ann For the first time, she saw herself as a future researcher, not just a technician or a student. to patient-centered research. Technical discipline is transferable—even across research cultures. The Importance of Passion in Research Catherine's journey highlights the importance of passion in research

  • Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline ...

    January 2022 Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline capabilities and personalised medicine platform from target identification through patient selection Research royalties PARIS & OXFORD, England & BOSTON--Sanofi and Exscientia announced today a groundbreaking research

  • Research Network on Signal Transduction (ERNEST) has established an Emergency Fund for Ukrainian ...

    March 2022 ERNEST has established an Emergency Fund for Ukrainian researchers. "General Eligibility Researchers affiliated to any legal entity in Ukraine (for example, schools and universities, research centers, governmental institutions, or private companies) Deadlines Start of the The purpose of the STSM is to carry out a collaborative research project on topics relevant to the network Our scientific perspective is broad, and we are happy to consider any research proposals from those in

  • Fentanyl and Xylazine: Why Breathing Fails in Overdose

    Watch Episode 172 The Bigger Picture: GPCR Science Meets Public Health At its core, Catherine Demery’s research street-level contamination rising faster than medicine can adapt, Catherine’s work shows why overdose research Catherine’s research confronts this problem head-on by asking: What actually happens to breathing when From Street Samples to Lab Models What makes Catherine’s research particularly powerful is how it stays Without research that keeps pace, clinical tools will always be one step behind.

  • β-arrestin1 and 2 exhibit distinct phosphorylation-dependent conformations when coupling to the...

    October 2022 β-arrestin1 and 2 exhibit distinct phosphorylation-dependent conformations when coupling to the same GPCR in living cells "β-arrestins mediate regulatory processes for over 800 different G protein-coupled receptors (GPCRs) by adopting specific conformations that result from the geometry of the GPCR-β-arrestin complex. However, whether β-arrestin1 and 2 respond differently for binding to the same GPCR is still unknown. Employing GRK knockout cells and β-arrestins lacking the finger-loop-region, we show that the two isoforms prefer to associate with the active parathyroid hormone 1 receptor (PTH1R) in different complex configurations ("hanging" and "core"). Furthermore, the utilisation of advanced NanoLuc/FlAsH-based biosensors reveals distinct conformational signatures of β-arrestin1 and 2 when bound to active PTH1R (P-R*). Moreover, we assess β-arrestin conformational changes that are induced specifically by proximal and distal C-terminal phosphorylation and in the absence of GPCR kinases (GRKs) (R*). Here, we show differences between conformational changes that are induced by P-R* or R* receptor states and further disclose the impact of site-specific GPCR phosphorylation on arrestin-coupling and function." Read more at the source #DrGPCR #GPCR #IndustryNews Subscribe to the Dr. GPCR Newsletter

  • Chronic itch: emerging treatments following new research concepts

    Currently, inhibitors of IL-31, IL-4/13, NK1 receptors, opioids and cannabinoids, JAK, PDE4 or TRP are the main

  • Cholesterol-Dependent Dynamics of the Serotonin1A Receptor Utilizing Single Particle Tracking: ...

    October 2022 Cholesterol-Dependent Dynamics of the Serotonin1A Receptor Utilizing Single Particle Tracking: Analysis of Diffusion Modes "G protein-coupled receptors (GPCRs) are signaling hubs in cell membranes that regulate a wide range of physiological processes and are popular drug targets. Serotonin1A receptors are important members of the GPCR family and are implicated in neuropsychiatric disorders. Cholesterol is a key constituent of higher eukaryotic membranes and is believed to contribute to the segregated distribution of membrane constituents into domains. To explore the role of cholesterol in lateral dynamics of GPCRs, we utilized single particle tracking (SPT) to monitor diffusion of serotonin1A receptors under acute and chronic cholesterol-depleted conditions. Our results show that the short-term diffusion coefficient of the receptor decreases upon cholesterol depletion, irrespective of the method of cholesterol depletion. Analysis of SPT trajectories revealed that relative populations of receptors undergoing various modes of diffusion change upon cholesterol depletion. Notably, in cholesterol-depleted cells, we observed an increase in the confined population of the receptor accompanied by a reduction in diffusion coefficient for chronic cholesterol depletion. These results are supported by our recent work and present observations that show polymerization of G-actin in response to chronic cholesterol depletion. Taken together, our results bring out the interdependence of cholesterol and actin cytoskeleton in regulating diffusion of GPCRs in membranes." Read more at the source #DrGPCR #GPCR #IndustryNews

  • Bell-Evans model and steered molecular dynamics in uncovering the dissociation kinetics of ligands..

    October 2022 Bell-Evans model and steered molecular dynamics in uncovering the dissociation kinetics of ligands targeting G-protein-coupled receptors "Recently, academic and industrial scientific communities involved in kinetics-based drug development have become immensely interested in predicting the drug target residence time. Screening drug candidates in terms of their computationally predicted residence times, which is a measure of drug efficacy in vivo, and simultaneously assessing computational binding affinities are becoming inevitable. Non-equilibrium molecular simulation approaches are proven to be useful in this purpose. Here, we have implemented an optimized approach of combining the data derived from steered molecular dynamics simulations and the Bell-Evans model to predict the absolute residence times of the antagonist ZMA241385 and agonist NECA that target the A2A adenosine receptor of the G-protein-coupled receptor (GPCR) protein family. We have predicted the absolute ligand residence times on the timescale of seconds. However, our predictions were many folds shorter than those determined experimentally. Additionally, we calculated the thermodynamics of ligand binding in terms of ligand binding energies and the per-residue contribution of the receptor. Subsequently, binding pocket hotspot residues that would be important for further computational mutagenesis studies were identified. In the experiment, similar sets of residues were found to be in significant contact with both ligands under study. Our results build a strong foundation for further improvement of our approach by rationalizing the kinetics of ligand unbinding with the thermodynamics of ligand binding." Read more at the source #DrGPCR #GPCR #IndustryNews

  • Production of human A2AAR in lipid nanodiscs for 19F-NMR and single-molecule fluorescence...

    August 2022 Production of human A 2A AR in lipid nanodiscs for 19 F-NMR and single-molecule fluorescence spectroscopy "We describe production of the human A2A adenosine receptor (A2AAR), a class A G protein-coupled receptor (GPCR) for 19F-NMR and single-molecule fluorescence (SMF) spectroscopy. We explain in detail steps shared between the two sample preparation strategies, including expression and isolation of A2AAR and assembly of A2AAR in lipid nanodiscs and procedures for incorporation of either 19F-NMR or fluorescence probes. Protocols for SMF experiments include sample setup, data acquisition, data processing, and error analysis. For complete details on the use and execution of this protocol, please refer to Wei et al. (2022) and Sušac et al. (2018)." Read more at the source #DrGPCR #GPCR #IndustryNews

  • Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for ...

    July 2022 Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators The grant should help expand Confo Therapeutic’s research on G protein-coupled receptor (GPCR) drug candidates

  • How GPCR Spatial Signaling Sparked a Scientific Journey

    Yet that summer research placement cracked open a new reality: the thrill of asking questions no one She went from reluctant intern to global researcher shaping how we understand GPCR spatial signaling. This pivot reflects a universal research truth: origin stories evolve—but the spark remains . For her, leadership in GPCR research is about enabling others to find their spark the way she found hers For GPCR research, leaders like Michelle are showing what happens when we follow the signal all the way

  • GPCR Collaboration: From Models to Medicine

    That perspective changed the moment he entered GPCR research . Instead, he acts as an advisor, helping research teams decide where modeling can accelerate progress—and The GPCR Challenge What makes collaboration non-negotiable in GPCR research is the biology itself. Whether in academia or biotech, the future belongs to research groups that can orchestrate ecosystems GPCR Models Don’t Discover Drugs—People Do In GPCR research, the biggest breakthroughs won’t come from

  • Competitive vs Non-Competitive GPCR Antagonists: How to Interpret Pharmacology Data with Confidence

    Career opportunities:  A curated list of new positions, including a Research Associate, a Senior Research Scientist, and a Post-doctoral Researcher position focused on GPCRs and Mitochondria. We’ve also highlighted the latest research on non-canonical internalization mechanisms of mGlu receptors Don't let misconceptions about receptor binding kinetics slow your progress—gain the clarity you need the actionable intelligence you need to make sense of these trends and integrate them into your own research

  • Using Live-cell High-Content Screening to Characterize CB2 Ligands: Insights From 16 Synthetic Cannabinoids

    receptor type 2 (CB2R) has emerged as a compelling target across inflammation, immune modulation, and pain research. By quantifying ligand–receptor interactions directly in intact cells, HCS allows researchers to observe Providing full tracer information ensures that researchers can recalculate or align affinity values across For researchers working in cannabinoid pharmacology, inflammation, or GPCR-mediated analgesia, these

  • The Perils and Guardrails of Modifying Signalling Proteins in Bioassays

    Drug discovery and development: Role of basic biological research. Biomedical researchers' perspectives on the reproducibility of research. G Protein-Coupled Receptors: A Century of Research and Discovery. The paradox from within: research participants doing-being-observed. Qualitative Research. 2015;16(4):446-467. 56.         Wilner W.

  • A NanoBRET-Based H 3 R Conformational Biosensor to Study Real-Time H 3 Receptor Pharmacology in...

    August 2022 A NanoBRET-Based H 3 R Conformational Biosensor to Study Real-Time H 3 Receptor Pharmacology in Cell Membranes and Living Cells "Conformational biosensors to monitor the activation state of G protein-coupled receptors are a useful addition to the molecular pharmacology assay toolbox to characterize ligand efficacy at the level of receptor proteins instead of downstream signaling. We recently reported the initial characterization of a NanoBRET-based conformational histamine H3 receptor (H3R) biosensor that allowed the detection of both (partial) agonism and inverse agonism on living cells in a microplate reader assay format upon stimulation with H3R ligands. In the current study, we have further characterized this H3R biosensor on intact cells by monitoring the effect of consecutive ligand injections in time and evaluating its compatibility with photopharmacological ligands that contain a light-sensitive azobenzene moiety for photo-switching. In addition, we have validated the H3R biosensor in membrane preparations and found that observed potency values better correlated with binding affinity values that were measured in radioligand competition binding assays on membranes. Hence, the H3R conformational biosensor in membranes might be a ready-to-use, high-throughput alternative for radioligand binding assays that in addition can also detect ligand efficacies with comparable values as the intact cell assay." Read more at the source #DrGPCR #GPCR #IndustryNews

bottom of page